Abbvie (ABBV) PT Raised to $126 at Mizuho Securities
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Needham Starts NeoVolta (NEOV) at Buy
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- KKR launches Helix with over $10 billion to build AI infrastructure
Abbvie (ABBV) PT Raised to $135 at RBC Capital
February 4, 2021 7:00 AM ESTRBC Capital analyst Randall Stanicky raised the price target on Abbvie (NYSE: ABBV) to $135.00 (from $129.00) while maintaining a Outperform rating. Overall, the outlook feels stable and very notably to Stanicky like a clear contrast to large cap biopharma peers dealing with mid-2020's... More
